Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7872711rdf:typepubmed:Citationlld:pubmed
pubmed-article:7872711lifeskim:mentionsumls-concept:C1335299lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C0009429lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:7872711lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:7872711pubmed:issue6Blld:pubmed
pubmed-article:7872711pubmed:dateCreated1995-3-30lld:pubmed
pubmed-article:7872711pubmed:abstractTextA 48-year-old woman with a nonresectable pancreatic tumor received combination chemotherapy with cytokines (IFN-a plus TNF-a) and 5-FU. Since partial response was confirmed after seven months, she underwent re-exploration, and received a pancreatico-duodenectomy. Histologically, the tumor was an adenosquamous carcinoma of the pancreas. She recovered uneventfully. However, the tumor rapidly recurred, and she died five months after surgery. Despite the poor result, the survival of the patient with advanced pancreatic cancer for twelve months after the staring of the treatment suggests that combined chemotherapy with cytokines and 5-FU may be a therapeutic modality for advanced pancreatic cancer.lld:pubmed
pubmed-article:7872711pubmed:languageenglld:pubmed
pubmed-article:7872711pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7872711pubmed:citationSubsetIMlld:pubmed
pubmed-article:7872711pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7872711pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7872711pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7872711pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7872711pubmed:statusMEDLINElld:pubmed
pubmed-article:7872711pubmed:issn0250-7005lld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:TanakaNNlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:OritaKKlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:IwagakiHHlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:MoreiraL FLFlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:OhoidaJJlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:MatunoTTlld:pubmed
pubmed-article:7872711pubmed:authorpubmed-author:GouchimAAlld:pubmed
pubmed-article:7872711pubmed:issnTypePrintlld:pubmed
pubmed-article:7872711pubmed:volume14lld:pubmed
pubmed-article:7872711pubmed:ownerNLMlld:pubmed
pubmed-article:7872711pubmed:authorsCompleteYlld:pubmed
pubmed-article:7872711pubmed:pagination2739-42lld:pubmed
pubmed-article:7872711pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:meshHeadingpubmed-meshheading:7872711-...lld:pubmed
pubmed-article:7872711pubmed:articleTitleResponse of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment.lld:pubmed
pubmed-article:7872711pubmed:affiliationFirst Department of Surgery, Okayama University Medical School, Japan.lld:pubmed
pubmed-article:7872711pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7872711pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7872711lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7872711lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7872711lld:pubmed